# Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment

> **NCT06304025** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle** · enrollment: 10 (estimated)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** Wharton's jelly mesenchymal stem cells (WJ-MSCs)

## Key facts

- **NCT ID:** NCT06304025
- **Lead sponsor:** Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-06
- **Primary completion:** 2025-06
- **Final completion:** 2025-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06304025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06304025, "Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06304025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*